Enzychem Lifesciences Corporation (183490.KQ) KOE
Currency In KRW
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Enzychem Lifesciences Corporation
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
122
First IPO Date
April 05, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Ki-Young Sohn | Chairman & Chief Executive Officer | 0 | N/A |
| John Choi | Executive Director | 0 | N/A |
| Myung-Hwan Kim | CMO & Director | 0 | N/A |
| Jeff Clark | Chief Licensing Officer | 0 | N/A |
| G. Alexander Fleming | Member of Corporate Advisory Committee & Chief Technology Officer | 0 | N/A |
| Jae-Yong Lee | Vice President & Executive Director | 0 | N/A |
| Do-Young Lee | Chief Scientific Officer & Member of the Board of Directors | 0 | N/A |
AD
Description
Enzychem Lifesciences Corporation, a pharmaceutical company, primarily dedicates itself to formulating oral, small-molecule therapies aimed at addressing urgent unmet medical needs for patients in South Korea suffering from conditions in oncology, metabolic diseases, and inflammatory disorders. Furthermore, the firm is actively developing innovative treatments utilizing its EC-18 technology platform to combat chemotherapy-induced neutropenia, oral mucositis triggered by chemoradiation therapy, and acute radiation syndrome. Founded in 1999, its headquarters are situated in Seoul, South Korea.
AD
